Open AccessRecrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy forPlasmodium vivaxMalaria
Author(s) -
Jean Popovici,
Lindsey Pierce-Friedrich,
Saorin Kim,
Sophalai Bin,
Vorleak Run,
Dysoley Lek,
KimHor Hee,
Lawrence Lee SoonU,
Matthew V. Can,
David Serre,
Didier Ménard
Publication year - 2018
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiy484
Subject(s) - plasmodium vivax , malaria , genotyping , chloroquine , drug resistance , biology , virology , piperaquine , medicine , plasmodium falciparum , immunology , genotype , genetics , gene , artemisinin
Plasmodium vivax resistance to chloroquine (CQ) has been reported worldwide, although the World Health Organization clinical drug efficacy studies protocol does not permit classification of patient outcomes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom